Literature DB >> 25862984

Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome.

Zhi-wei Lai1, Ivan Marchena-Mendez1, Andras Perl2.   

Abstract

Anti-phospholipid antibodies (APLA) represent a diagnostic criterion of systemic lupus erythematosus (SLE) and cause morbidity, termed anti-phospholipid syndrome (APS). Activation of the mechanistic target of rapamycin (mTOR) has been recently associated with APS. mTOR is a sensor of oxidative stress. Therefore, we examined mitochondrial mass, superoxide production, mTOR activity and FoxP3 expression in 72 SLE patients, twelve of whom also had APS, and 54 healthy controls by flow cytometry. Mitochondrial mass was increased in CD4(-)CD8(-) double-negative (DN) T cells of SLE patients with APS (2.7-fold) in comparison to those without APS (1.7-fold; p = 0.014). Superoxide production was increased in all lymphocyte subsets of APS patients. FoxP3(+) cells were depleted within CD4(+)CD25(+) Tregs in patients with APS (28.4%) relative to those without APS (46.3%, p = 0.008). mTOR activity was similar between SLE patients with and without APS. Thus, oxidative stress and Treg depletion rather than mTOR activation underlie APS in patients with SLE.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-phospholipid syndrome; Mechanistic target of rapamycin; Oxidative stress; Systemic lupus erythematosus; Treg; mTOR

Mesh:

Substances:

Year:  2015        PMID: 25862984      PMCID: PMC4464983          DOI: 10.1016/j.clim.2015.03.024

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  32 in total

1.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus.

Authors:  Edward Doherty; Zachary Oaks; Andras Perl
Journal:  Antioxid Redox Signal       Date:  2014-04-23       Impact factor: 8.401

4.  Inhibition of the mTORC pathway in the antiphospholipid syndrome.

Authors:  Guillaume Canaud; Frank Bienaimé; Fanny Tabarin; Guillaume Bataillon; Danielle Seilhean; Laure-Hélène Noël; Marie-Agnès Dragon-Durey; Renaud Snanoudj; Gérard Friedlander; Lise Halbwachs-Mecarelli; Christophe Legendre; Fabiola Terzi
Journal:  N Engl J Med       Date:  2014-07-24       Impact factor: 91.245

5.  Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation.

Authors:  David R Fernandez; Tiffany Telarico; Eduardo Bonilla; Qing Li; Sanjay Banerjee; Frank A Middleton; Paul E Phillips; Mary K Crow; Stefanie Oess; Werner Muller-Esterl; Andras Perl
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

6.  T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis.

Authors:  S Shivakumar; G C Tsokos; S K Datta
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

7.  N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Zhi-Wei Lai; Robert Hanczko; Eduardo Bonilla; Tiffany N Caza; Brandon Clair; Adam Bartos; Gabriella Miklossy; John Jimah; Edward Doherty; Hajra Tily; Lisa Francis; Ricardo Garcia; Maha Dawood; Jianghong Yu; Irene Ramos; Ioana Coman; Stephen V Faraone; Paul E Phillips; Andras Perl
Journal:  Arthritis Rheum       Date:  2012-09

Review 8.  Oxidative stress in the pathology and treatment of systemic lupus erythematosus.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2013-10-08       Impact factor: 20.543

9.  Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus.

Authors:  Peter Gergely; Craig Grossman; Brian Niland; Ferenc Puskas; Hom Neupane; Fatme Allam; Katalin Banki; Paul E Phillips; Andras Perl
Journal:  Arthritis Rheum       Date:  2002-01

10.  Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.

Authors:  Zhi-Wei Lai; Rebecca Borsuk; Ashwini Shadakshari; Jianghong Yu; Maha Dawood; Ricardo Garcia; Lisa Francis; Hajra Tily; Adam Bartos; Stephen V Faraone; Paul Phillips; Andras Perl
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

View more
  13 in total

1.  Association between paraoxonase-1 gene Q192R and L55M polymorphisms in systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS) in a population from Cairo of Egypt.

Authors:  Alshaymaa Ahmed Ibrahim; Dalia El-Lebedy; Ingy Ashmawy; Maha Abdel Hady
Journal:  Clin Rheumatol       Date:  2017-02-09       Impact factor: 2.980

Review 2.  Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.

Authors:  Zachary Oaks; Thomas Winans; Nick Huang; Katalin Banki; Andras Perl
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

Review 3.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

4.  Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus.

Authors:  Yuxin Liu; Jianghong Yu; Zachary Oaks; Ivan Marchena-Mendez; Lisa Francis; Eduardo Bonilla; Phillip Aleksiejuk; Jessica Patel; Katalin Banki; Steve K Landas; Andras Perl
Journal:  Clin Immunol       Date:  2015-07-06       Impact factor: 3.969

Review 5.  Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis.

Authors:  Tiffany Caza; Chathura Wijewardena; Laith Al-Rabadi; Andras Perl
Journal:  Transl Res       Date:  2022-03-12       Impact factor: 10.171

6.  Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.

Authors:  Elliot H Akama-Garren; Michael C Carroll
Journal:  J Immunol       Date:  2022-04-27       Impact factor: 5.426

Review 7.  Oxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus Erythematosus.

Authors:  Ji Yang; Xue Yang; Hejian Zou; Ming Li
Journal:  Oxid Med Cell Longev       Date:  2016-08-11       Impact factor: 6.543

8.  Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.

Authors:  Loukman Omarjee; Anne Janin; Frédérique Perrot; Bruno Laviolle; Olivier Meilhac; Guillaume Mahe
Journal:  Clin Immunol       Date:  2020-05-13       Impact factor: 3.969

Review 9.  T Cell Homeostatic Proliferation Promotes a Redox State That Drives Metabolic and Epigenetic Upregulation of Inflammatory Pathways in Lupus.

Authors:  Ralph C Budd; Christopher D Scharer; Ramiro Barrantes-Reynolds; Scott Legunn; Karen A Fortner
Journal:  Antioxid Redox Signal       Date:  2021-11-09       Impact factor: 8.401

10.  The Emerging Epigenetic Role of CD8+T Cells in Autoimmune Diseases: A Systematic Review.

Authors:  Qiancheng Deng; Yangyang Luo; Christopher Chang; Haijing Wu; Yan Ding; Rong Xiao
Journal:  Front Immunol       Date:  2019-04-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.